Edesa Biotech Prepares Phase 2 Vitiligo Trial for Mid-2026 Launch Following Promising ARDS Results
Key Insights
Edesa Biotech is preparing to initiate a Phase 2 trial of EB06, an anti-CXCL10 (search) monoclonal antibody, for moderate-to-severe non-segmental vitiligo (search) patients in mid-2026.
The planned study will enroll approximately 160 patients and evaluate three different doses of EB06 administered intravenously every two weeks for up to 24 weeks.
Updated Phase 3 ARDS (search) results showed paridiprubart achieved a 27% relative reduction in 28-day mortality risk compared to placebo in the full 278-patient population.
Edesa Biotech, Inc. (NASDAQ:EDSA) is advancing preparations for a Phase 2 clinical trial of EB06, its anti-CXCL10 (search) monoclonal antibody, targeting moderate-to-severe non-segmental vitiligo (search) patients with enrollment expected to begin in mid-2026. The company has already received approval from Health Canada to conduct the Phase 2 trial and is currently preparing an IND submission for FDA review.
Addressing Significant Unmet Medical Need
Vitiligo (search) affects an estimated 1.9 million to 2.8 million patients in the U.S., representing a market projected to reach approximately $1.2 billion by 2030. The autoimmune disease causes areas of skin to lose color when pigment-producing melanocytes die or stop producing melanin. Currently, the only FDA-approved therapy is topical ruxolitinib (Opzelura®), which generated $678 million in revenue in 2025, with approximately $390 million from vitiligo sales. However, Opzelura carries a black-box warning due to potential serious infections, major adverse cardiovascular events, and thrombosis.
EB06 Mechanism and Clinical Design
EB06 specifically targets CXCL10 (search), a chemokine elevated in both vitiligo (search) patient skin and serum. Research has demonstrated that CXCL10 plays a key role in trafficking anti-melanocytic T-cells to the epidermis and directly induces melanocyte cell death via CXCR3B (search) activation. In preclinical mouse models of vitiligo, neutralization of CXCL10 induced disease reversal through repigmentation in mice with established, widespread depigmentation.
The planned Phase 2 study will enroll approximately 160 patients with severe nonsegmental vitiligo (search) and evaluate three different doses of EB06 (2.5 mg/kg, 5 mg/kg, 10 mg/kg) administered intravenously every two weeks for up to 24 weeks, followed by a 12-week follow-up period. The primary efficacy endpoint will measure the percentage of patients achieving ≥50% decrease from baseline in facial Vitiligo Area Scoring Index (F-VASI50), a composite measurement of overall facial vitiligo patch area and degree of depigmentation.
Results from 65 subjects in three previous clinical studies demonstrated that EB06 produced the required pharmacodynamic and biological activity to address the dysfunctional immune response associated with vitiligo (search), while being generally safe and well-tolerated.
Strong ARDS Program Results Support Regulatory Discussions
In February 2026, Edesa announced updated Phase 3 results for paridiprubart (EB05) in acute respiratory distress syndrome (search) (ARDS (search)) from the full 278-patient safety population. The data showed 28-day adjusted mortality was 24% on paridiprubart plus standard-of-care compared to 33% on placebo plus standard-of-care, representing a 27% relative reduction in risk of death (P<0.001).
Exploratory analyses across clinically relevant subgroups consistently showed reduced adjusted mortality with paridiprubart treatment:
- Acute Kidney Injury patients (n=48): 35% relative reduction (35% vs. 53%; P<0.05)
- Sepsis patients (n=41): 36% relative reduction (40% vs. 63%; P<0.05)
- Pneumonia patients (n=108): 30% relative reduction (35% vs. 49%; P<0.05)
The safety profile remained consistent with prior exposures, showing similar rates of adverse events and infections compared to placebo. Over 400 patients have now received paridiprubart treatment.
Financial Position and Manufacturing Progress
For the second quarter of fiscal year 2026 ended March 31, 2026, Edesa reported R&D expenses of $2.8 million, compared to $0.5 million in the prior year period. The increase was primarily attributed to higher manufacturing costs and preparations for the planned Phase 2 vitiligo (search) study. As of March 31, 2026, the company maintained approximately $10.0 million in cash and cash equivalents.
Edesa has initiated manufacturing activities to supply drug product for the Phase 2 trial and begun outreach to potential investigators. The company currently has approximately 8.9 million shares outstanding, with a fully diluted share count of approximately 15.7 million when including stock options, warrants, and Series B-1 convertible preferred shares.
Management plans to engage with regulatory agencies in both the U.S. and Canada to determine the most appropriate regulatory pathway for paridiprubart, with discussions likely focusing on whether the mortality and clinical improvement signals support a registrational submission and potential accelerated approval pathways given the high unmet need in ARDS (search) treatment.